The First Case Report of De Novo Crohn's Disease After Heart Transplantation Successfully Treated with Ustekinumab
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Learning Objective: Colitis is a common complication after heart transplantation (HTx). Although cytomegalovirus colitis or posttransplant lymphoproliferative disorder are observed commonly, de novo inflammatory bowel disease (IBD) should be considered when serious refractory colitis occurs. Not only 5-aminosalicylic acid but also ustekinumab, which is a monoclonal antibody to the p40 subunit of interleukin (IL)-12 and IL-23, may be a safe and effective treatment for de novo IBD after HTx.
References
1.
Lashgari N, Roudsari N, Momtaz S, Ghanaatian N, Kohansal P, Farzaei M
. Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases. Curr Med Chem. 2020; 28(8):1605-1624.
DOI: 10.2174/0929867327666200504081503.
View
2.
Hiraoka S, Fujiwara A, Toyokawa T, Higashi R, Moritou Y, Takagi S
. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol. 2020; 36(1):137-143.
DOI: 10.1111/jgh.15138.
View
3.
Shibuya T, Nomura O, Nagahara A
. Safety and Efficacy of Ustekinumab for Ulcerative Colitis in a Liver Transplant Patient. Inflamm Bowel Dis. 2021; 27(12):e150-e151.
DOI: 10.1093/ibd/izab169.
View
4.
Neurath M
. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014; 14(5):329-42.
DOI: 10.1038/nri3661.
View
5.
Allen P, Peyrin-Biroulet L
. Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. Expert Rev Clin Immunol. 2016; 12(7):741-9.
DOI: 10.1586/1744666X.2016.1154789.
View